Patents by Inventor Robert D. Fleischmann
Robert D. Fleischmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6416984Abstract: The invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a procedure for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: GrantFiled: June 6, 1995Date of Patent: July 9, 2002Assignee: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen
-
Publication number: 20020061527Abstract: Disclosed is a human is a hTopI-&agr; polypeptide and DNA (RNA) encoding such hTopI-&agr; polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the antibodies and antagonist inhibitors to inhibit the action of hTopI-&agr; for therapeutic purposes such as an antitumor agent, to detect an autoimmune disease, or retroviral infections and to treat adenocarcinoma of the colon. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.Type: ApplicationFiled: June 4, 2001Publication date: May 23, 2002Inventors: Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann
-
Patent number: 6380369Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins which may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: August 23, 1994Date of Patent: April 30, 2002Assignee: Human Genome Sciences, Inc.Inventors: Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, William A. Haseltine, Craig A. Rosen, Steve Ruben, Ying-Fei Wei
-
Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
Patent number: 6355450Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: GrantFiled: June 7, 1995Date of Patent: March 12, 2002Assignee: Human Genome Sciences, Inc.Inventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter -
Publication number: 20020015980Abstract: Disclosed is a neurotransmitter transporter protein and DNA (RNA) encoding such protein. Also provided is a procedure for producing such polypeptide by recombinant techniques. The procedure for producing antagonists/inhibitors against such polypeptide is also provided. Such antagonists/inhibitors may be used to inhibit the action of neurotransmitter transporter protein for treatment of depression, anxiety of epilepsy.Type: ApplicationFiled: August 8, 2001Publication date: February 7, 2002Inventors: Yi Li, Robert D. Fleischmann
-
Patent number: 6255077Abstract: Disclosed is a human is a hTopI-&agr; polypeptide and DNA (RNA) encoding such hTopI-&agr; polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the antibodies and antagonist inhibitors to inhibit the action of hTopI-&agr; for therapeutic purposes such as an antitumor agent, to detect an autoimmune disease, or retroviral infections and to treat adenocarcinoma of the colon. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.Type: GrantFiled: June 4, 1999Date of Patent: July 3, 2001Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann
-
Patent number: 6147050Abstract: Disclosed is a human FLAP II polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Further, antagonists against such polypeptide are disclosed. Such antagonists may be used for therapeutic proposes, for example, for treating inflamation, bronchial asthma and may also be used as gastric cytoprotective agents and to treat human glomerulonephritis. Diagnostic assays for identifying mutations in nucleic acid sequences encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.Type: GrantFiled: April 22, 1997Date of Patent: November 14, 2000Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Robert D. Fleischmann
-
Patent number: 5994103Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of electrolyte disorders which lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use therapeutically to treat hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha seqeunces is also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: November 30, 1999Assignee: Human Genome Science, Inc.Inventors: Henrik S. Olsen, Robert D. Fleischmann
-
Patent number: 5968803Abstract: Disclosed is a human is a hTopI-.alpha. polypeptide and DNA (RNA) encoding such hTopI-.alpha. polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the antibodies and antagonist inhibitors to inhibit the action of hTopI-.alpha. for therapeutic purposes such as an antitumor agent, to detect an autoimmune disease, or retroviral infections and to treat adenocarcinoma of the colon. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.Type: GrantFiled: March 2, 1998Date of Patent: October 19, 1999Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann
-
Patent number: 5869284Abstract: Disclosed is a retinoic acid receptor epsilon (RAR.epsilon.) polynucleotide and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, tissue regeneration and stimulation of the immune and hematopoietic system. Also disclosed are methods of identifying ligands which stimulate the RAR.epsilon.. Also disclosed are diagnostic methods for detecting a mutation in the RAR.epsilon. receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: GrantFiled: June 6, 1995Date of Patent: February 9, 1999Assignee: Human Genome Sciences, Inc.Inventors: Liang Cao, Jian Ni, Robert D. Fleischmann
-
Patent number: 5759854Abstract: Disclosed is a neurotransmitter transporter protein and DNA (RNA) encoding such protein. Also provided is a procedure for producing such polypeptide by recombinant techniques. The procedure for producing antagonists/inhibitors against such polypeptide is also provided. Such antagonists/inhibitors may be used to inhibit the action of neurotransmitter transporter protein for treatment of depression, anxiety of epilepsy.Type: GrantFiled: April 21, 1995Date of Patent: June 2, 1998Assignee: Human Genome Sciences, Inc.Inventors: Yi Li, Robert D. Fleischmann
-
Patent number: 5723311Abstract: Disclosed is a human is a hTopI-.alpha. polypeptide and DNA (RNA) encoding such hTopI-.alpha. polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the antibodies and antagonist inhibitors to inhibit the action of hTopI-.alpha. for therapeutic purposes such as an antitumor agent, to detect an autoimmune disease, or retroviral infections and to treat adenocarcinoma of the colon. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: March 3, 1998Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann
-
Patent number: 5696076Abstract: Disclosed is a human FLAP II polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Further, antagonist/inhibitors against such polypeptide are disclosed. Such antagonist/inhibitors may be used for therapeutic purposes, for example, for treating inflammation, bronchial asthma and may also be used as gastric cytoprotective agents and to treat human glomerulonephritis.Type: GrantFiled: June 22, 1994Date of Patent: December 9, 1997Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Robert D. Fleischmann